What Is T-Cell Lymphoma?

What Is T-Cell Lymphoma?
Adobe Stock; Everyday Health
T-cell lymphoma (TCL) is a rare form of cancer that affects the lymphatic system.

It develops from the abnormal multiplication of T cells, or T-lymphocytes, a type of white blood cell essential for immune system function.

The specific treatment course and prognosis for T-cell lymphoma depends on the subtype — of which there are many — and how advanced the cancer is.

Types of Lymphoma

There are two types of lymphoma:

  • Hodgkin lymphoma (formerly Hodgkin disease)
  • non-Hodgkin lymphoma

Hodgkin lymphoma involves a type of cancer cell called Reed-Sternberg cells. Unlike Hodgkin lymphoma, the non-Hodgkin varieties look different under the microscope and don’t contain Reed-Sternberg cells. T-cell lymphoma is a type of non-Hodgkin lymphoma.

Non-Hodgkin lymphomas either begin in B cells or T cells — T-cell lymphomas account for less than 15 percent of all non-Hodgkin lymphomas.

Types of T-Cell Lymphoma

The two main categories of T-cell lymphoma are:

  • Cutaneous T-cell lymphoma
  • Peripheral T-cell lymphoma
Typically slow-growing, cutaneous T-cell lymphoma (CTCL) is the most common form of T-cell lymphoma.

It mainly affects the skin — though they’re not classified as skin cancers — but can also affect lymph nodes, blood, and internal organs.

Peripheral T-cell lymphomas are a diverse group of cancers that primarily affect lymph nodes and other lymph tissues. There are 19 different subtypes that are usually aggressive.

Signs and Symptoms of T-Cell Lymphoma

Given its many different subtypes, T-cell lymphoma can present with a wide range of signs and symptoms, and its manifestations may vary from person to person. For instance, the first signs of a type of T-cell lymphoma called mycosis fungoides is often a skin rash, while other forms may present with swollen lymph nodes.

Common symptoms for cutaneous T-cell lymphoma include:

  • Red rash that may look like a sunburn and is intensely itchy
  • Round scaly patches of skin that may be raised
  • Light or white patches of skin
  • Thick, raised plaques
  • Skin lesions, including ulcers or nodules, that may break open
  • Skin tumors that may be bluish or reddish brown
  • Changes to nails and hair, including hair loss
  • Thickened skin on the palms of hands and soles of feet
  • Skin peeling
  • Insomnia (from itching)
Aggressive forms of T-cell lymphoma may include symptoms like hypercalcemia (too much calcium in the blood), bone pain, and confusion.

Signs and symptoms for other types of T-cell lymphoma include:

  • Swollen lymph nodes, particularly in the neck, armpit, or groin
  • Fever or chills
  • Unexplained fatigue
  • Unexplained weight loss
  • Night sweats
  • Respiratory issues such as coughing, shortness of breath, or chest pain
  • Gastrointestinal symptoms such as abdominal pain, nausea, vomiting, constipation, or diarrhea
  • Frequent urination
  • Enlarged liver or spleen
  • Bleeding or bruising easily
  • Recurrent infections
If the cancer spreads to the brain, it may also cause:

  • Headaches
  • Concentration problems
  • Personality changes
  • Seizures

Causes and Risk Factors for T-Cell Lymphoma

The causes of the majority of T-cell lymphomas are unknown.

Acquired genetic mutations usually have a role to play, but external factors — including viruses and chemical exposure — may also contribute to causing T-cell lymphomas.

You have an increased risk of developing T-cell lymphoma if you:

  • Are age 55 or older
  • Are male or assigned male at birth
  • Are white or Asian
  • Have a weakened immune system due to conditions like HIV/AIDS or immunosuppressive therapies following organ transplantation
  • Have a family history of lymphoma or other blood cancers
  • Have prolonged exposure to carcinogens such as ultraviolet light, chemicals, pesticides, or environmental toxins
  • Have certain viral infections, such as Epstein-Barr virus and HTLV-1 (human T-lymphotropic virus 1)
  • Have certain autoimmune diseases, such as celiac disease

How Is T-Cell Lymphoma Diagnosed?

Diagnosing T-cell lymphoma involves a combination of medical and family history review, physical examination, and various diagnostic tests.

During the physical examination, your healthcare provider will look for evidence of lymph nodes that can be felt through the skin, skin abnormalities, or other signs indicative of T-cell lymphoma.
Tests that may be used to diagnose T-cell lymphoma include:

  • Blood tests to evaluate the number and types of blood cells, and to assess organ function and overall health
  • Peripheral blood smear, an examination of blood cells and platelets under the microscope

  • CT, PET, or MRI scans to identify enlarged lymph nodes or organs affected by lymphoma and areas with abnormal cell growth
  • Biopsy of any enlarged lymph nodes or involved skin (to confirm lymphoma and determine its subtype)
  • Immunophenotyping, a lab test that helps diagnose specific lymphoma types

  • Bone marrow aspiration (a procedure that removes a small sample of bone marrow) and biopsy to determine if the disease has spread to the bone marrow
  • Flow cytometry, a test used to identify specific types of lymphoma cells
  • Collection and testing of cerebrospinal fluid to determine if the lymphoma has spread to the central nervous system
  • Tests for various viruses including HIV, HTLV-1, and Epstein-Barr virus

Your healthcare provider may also run tests to identify specific genetic mutations or molecular markers to further characterize the lymphoma and guide treatment decisions.

Accurately diagnosing T-cell lymphoma often takes time. Given that cutaneous T-cell lymphoma shares symptoms with many other benign conditions, it takes an average of 6 years from disease onset to reach a correct diagnosis.

During diagnosis, your healthcare provider will also determine the stage of your disease, which is crucial for developing an effective treatment plan.

Stages of T-Cell Lymphoma

T-cell lymphoma is typically defined as being stage 1 through 4, which indicates the extent of the cancer.

  • Stage 1 The cancer is limited to a single lymph node region or a single lymphoid organ, which includes the thymus, spleen, and bone marrow.
  • Stage 2 The cancer involves two or more lymph node regions on the same side of the diaphragm, a major breathing muscle located below the lungs.
  • Stage 3 The cancer involves lymph node regions on both sides of the diaphragm, above or below it, or your spleen.
  • Stage 4 The cancer has spread to organs beyond the lymphatic system, such as the liver, lungs, or bone marrow.
Cutaneous T-cell lymphoma has a different growth pattern than other types of lymphoma, and staging may be based on the presence of various symptoms:

  • Stage 1A Limited patches, papules, or plaques covering less than 10 percent of the skin surface. No tumors are present, and lymph nodes, blood, and internal organs are not involved.
  • Stage 1B Same as stage 1A but skin issues cover more than 10 percent of the skin surface.
  • Stage 2A Lymph nodes are abnormal but not cancerous.
  • Stage 2B One or more tumors 1 centimeter or larger develops on the skin. Lymph nodes are not cancerous.
  • Stage 3 At least 80 percent of the skin surface is reddened and covered with patches, papules, plaques, or tumors.
  • Stage 4A There is a high number of Sézary cells, or cancerous T-cells, in the blood.
  • Stage 4A2 There may be a high number of Sézary cells in the blood, and the lymph nodes are very abnormal or have developed cancer.
  • Stage 4B The cancer has spread to other organs, such as the spleen or liver.

T-Cell Lymphoma Treatment Options

Treatment plans are tailored to each patient, considering factors such as age, overall health, the specific characteristics of the T-cell lymphoma subtype, and stage of the disease.

Options for treatment cover a wide range of medications, procedures, and therapies.

Medication Options

Medication options may include:

  • Topical corticosteroids, like clobetasol propionate

  • Retinoids (drugs related to vitamin A), like bexarotene

     in the form of creams, gels, and ointments to help control redness and itchiness
  • Topical chemotherapy drugs like mechlorethamine

  • Intravenous chemotherapy drugs like doxorubicin (Adriamycin) and pralatrexate (Folotyn)

  • Antiviral drugs such as zidovudine (Retrovir), if there is a viral infection

  • Immunotherapy medications that stimulate or boost the body's immune system to recognize and attack cancer cells, including alemtuzumab (Campath, Lemtrada) and denileukin diftitox (Ontak), imiquimod (Zyclara), and pembrolizumab (Keytruda)
  • Targeted therapy medications that focus on specific molecular changes or proteins in or on cancer cells

Surgery

Surgery options include:

  • Tumor resection to remove tumors
  • Stem cell transplantation,  a procedure to replace damaged bone marrow cells with stem cells (immature blood cells), which may require general anesthesia

Other Treatments and Procedures

Nonmedication treatment options may include:

  • Extracorporeal photopheresis, a procedure in which your blood is removed and treated with UV lights and light-activated drugs before being returned to your body
  • Radiation therapy to eliminate cancer cells, particularly when the disease is localized
  • Phototherapy, or using ultraviolet (UV) light to kill cancer cells in the skin

Lifestyle Approaches

While T-cell lymphoma requires thorough medical treatment, there are things you can do to encourage positive treatment outcomes.

These include:

  • Light exercise to maintain physical strength and reduce fatigue
  • A nutrient-rich diet of lean meats, fruits, and vegetables, especially cruciferous vegetables like broccoli and cauliflower

  • Palliative care for emotional and psychological support
  • Complementary therapies for symptom relief with the support of your doctor
In the case of cutaneous T-cell lymphoma:

  • Use mild, unscented soaps to prevent skin irritation.
  • Keep skin moisturized to prevent itching and infection.
  • Discuss bleach baths with your healthcare provider to reduce infection.

Clinical Trials

Researchers may be testing new therapies to help with conditions like T-cell lymphoma. If you're interested in participating in a clinical trial, speak with your doctor or visit ClinicalTrials.gov to search for studies in your area.

T-Cell Lymphoma Prevention

There is no definite way to prevent T-cell lymphoma. Most often, people with T-cell lymphoma have no risk factors that can be changed. But a level of awareness and certain lifestyle choices can reduce some risks, contribute to early detection, and lead to better overall prognosis. These include:

  • Routine health checkups and screenings to aid in the early detection of lymphoma.
  • Awareness of potential symptoms, and medical advice for persistent issues
  • A healthy weight, physical activity, and a healthy diet
  • Minimal exposure to environmental challenges, such as certain chemicals or pollutants
  • Avoidance of risk factors for HIV (which increases the risk of T-cell lymphoma) and HTLV-1, including intravenous drug use and unprotected sex

T-Cell Lymphoma Prognosis and Survival Rates

T-cell lymphoma prognosis varies widely based on the specific subtype, stage at diagnosis, and individual patient factors. Generally, T-cell lymphomas tend to have a more aggressive course than some B-cell lymphomas.

Younger people, those diagnosed early, and those with localized disease that hasn't spread through the body tend to have better outcomes.

Survival rates can be influenced by:

  • Subtype: Different subtypes have distinct prognoses, with some being more responsive to treatment than others.
  • Stage at diagnosis: Early-stage T-cell lymphomas often have a more favorable prognosis than those diagnosed at an advanced stage.
  • Age and overall health: Younger patients and those in good overall health may respond better to treatment.
  • Response to treatment: How well the cancer responds to initial treatment can significantly influence the prognosis.
The overall five-year relative survival rate for non-Hodgkin lymphoma is 74.3 percent.

It accounts for 3.3 percent of all cancer deaths. The survival rate for early-stage cutaneous T-cell lymphoma over 10 years is roughly 90 percent, while late stage CTCL survival rates are about 53 percent.

For peripheral T-cell lymphoma, the five-year survival rate is between 30 and 40 percent.

It's crucial for you to discuss prognosis and potential treatment outcomes with your healthcare provider, as individual cases can vary widely.

Complications of T-Cell Lymphoma

T-cell lymphoma can lead to serious complications, including organ damage or life-threatening infections.

Organ damage can occur when tumors penetrate areas like the spleen, liver, or bone marrow.

Immune suppression or immune system reactions to tumors can lead to infections.

Research and Statistics: Who Has T-Cell Lymphoma?

T-cell lymphomas are rare, making up 10 to 15 percent of all non-Hodgkin lymphomas. They are slightly more common in men or people assigned male at birth.

T-cell lymphomas occur more often in locations like Japan, China, the Caribbean, South and Central America, and West Africa, where HTLV-1 infections are more common.

Related Conditions to T-Cell Lymphoma

Related conditions include:

  • Other non-Hodgkin lymphomas, like B-cell lymphoma
  • Skin conditions mimicking cutaneous T-cell lymphoma, like psoriasis and eczema

  • Autoimmune disorders like hemophagocytic syndrome
  • Leukemia
  • Some extracutaneous lymphomas, like systemic T-cell lymphoma

T-cell lymphoma may present as inflammatory skin diseases like psoriasis or dermatitis in the early stages, sometimes making diagnosis more complicated.

Support for T-Cell Lymphoma

People with T-cell lymphoma can support each other and share effective ways to manage the disease. One of these organizations may offer the resources you need.

Leukemia & Lymphoma Society (LLS)

LLS is the largest nonprofit dedicated to curing blood cancers, including leukemia, lymphoma, Hodgkin’s disease, and myeloma. It provides patient education, offers financial assistance, and advocates for policies to improve access to care and encourage treatment development.

Lymphoma Research Foundation (LRF)

The Lymphoma Research Foundation is the largest U.S. nonprofit focused exclusively on lymphoma. It funds innovative research to advance treatments and cures while providing education, support services, and resources for patients and caregivers. LRF also connects people with lymphoma through its peer-to-peer Lymphoma Support Network.

CancerCare

CancerCare is a national nonprofit offering free professional support services for individuals affected by cancer, including counseling, support groups, educational workshops, and financial assistance.

The T-Cell Leukemia & Lymphoma Foundation (TCLLF)

The TCLLF supports patients with rare T-cell cancers by funding research, hosting educational forums, promoting clinical trial participation, and raising awareness about these rare diseases.

The Takeaway

  • T-cell lymphoma is a rare cancer that affects the lymphatic system.
  • It develops from the abnormal multiplication of T cells, a type of white blood cell.
  • Treatment and prognosis for T-cell lymphoma depends on the subtype and how far the cancer has progressed.
  • The overall five-year relative survival rate for non-Hodgkin lymphomas like T-cell is 74.3 percent.

Common Questions & Answers

How serious is T-cell lymphoma?

T-cell lymphoma is considered serious because of its aggressive nature and poorer outcomes compared with B-cell lymphomas.

Survival rates for T-cell lymphomas vary by subtype and stage. Early-stage lymphomas have a 10-year survival rate of about 90 percent, while survival rates for aggressive or advanced-stage lymphomas are roughly 53 precent.

The early symptoms of T-cell lymphoma may include swollen lymph nodes, skin rashes or lesions, fatigue, fever, weight loss, and night sweats. Aggressive forms of T-cell lymphoma may include hypercalcemia (too much calcium in the blood), bone pain, and confusion.

T-cell lymphoma originates in a mature type of white blood cell known as T-cells. It often begins in the lymph nodes, but may also start in the skin, blood, or other organs.

Additional reporting by Crystal Hoshaw.

EDITORIAL SOURCES
Everyday Health follows strict sourcing guidelines to ensure the accuracy of its content, outlined in our editorial policy. We use only trustworthy sources, including peer-reviewed studies, board-certified medical experts, patients with lived experience, and information from top institutions.
Resources
  1. T-cell Lymphoma. Cleveland Clinic. April 26, 2023.
  2. Pruthi RK. Hodgkin's vs. non-Hodgkin's Lymphoma: What's the Difference? Mayo Clinic. January 10, 2023.
  3. Types of T-cell Lymphoma. American Cancer Society. February 15, 2024.
  4. Non-Hodgkin Lymphoma. Cleveland Clinic. August 5, 2022.
  5. T-cell lymphomas (TCL). Leukemia and Lymphoma Society. 2020.
  6. Mayo Clinic Staff. Cutaneous T-cell lymphoma. Mayo Clinic. February 9, 2023.
  7. Peripheral T-cell Lymphoma (PTCL). Cleveland Clinic. June 27, 2023.
  8. T-cell lymphomas. Lymphoma Action.
  9. Types of T-cell Lymphoma. American Cancer Society. February 15, 2024.
  10. Non-Hodgkin lymphoma. MedlinePlus. February 2, 2023.
  11. Peripheral T-cell lymphoma. Leukaemia Foundation. May 22, 2024.
  12. Non-Hodgkin Lymphoma Risk Factors. American Cancer Society. February 15, 2024.
  13. Mayo Clinic Staff. Cutaneous T-cell Lymphoma. Mayo Clinic. February 9, 2023.
  14. Peripheral Blood Smear. Cleveland Clinic. April 15, 2022.
  15. Varghese MT et al. T-Cell Lymphoma. StatPearls. March 13, 2024.
  16. Cutaneous T-Cell Lymphoma. Johns Hopkins Medicine.
  17. Gellar S et al. Topical Clobetasol Propionate Treatment and Cutaneous Adverse Effects in Patients with Early-Stage Mycosis Fungoides: An Observational Study. CUTIS. May 2020.
  18. Fujimura T et al. Topical and Systemic Formulation Options for Cutaneous T Cell Lymphomas. Pharmaceutics. February 2, 2021.
  19. Mechlorethamine Topical. MedlinePlus. February 15, 2017.
  20. Kciuk M et al. Doxorubicin — an Agent with Multiple Mechanisms of Anticancer Activity. Cells. February 19, 2023.
  21. O’Donnell JS et al. Human T-lymphotropic Virus Type 1 and Antiretroviral Therapy: Practical Considerations for Pre-Exposure and Post-Exposure Prophylaxis, Transmission Prevention, and Mitigation of Severe Disease. Lancet. April 2024.
  22. Treating T-Cell Non-Hodgkin Lymphoma. American Cancer Society. February 15, 2024.
  23. How Is Cutaneous T-Cell Lymphoma Treated? Boston Medical.
  24. Cutaneous T-cell Lymphoma. Mayo Clinic. February 9, 2023.
  25. Baladia E et al. Broccoli Consumption and Risk of Cancer: An Updated Systematic Review and Meta-Analysis of Observational Studies. Nutrients. May 23, 2024.
  26. Marino P et al. Healthy Lifestyle and Cancer Risk: Modifiable Risk Factors to Prevent Cancer. Nutrients. March 11, 2024.
  27. T-Cell Lymphoma. Lymphoma Research Foundation.
  28. How Long Will I Live With T-Cell Lymphoma? HealthTree Foundation.
  29. Mycosis Fungoides and Other Cutaneous T-Cell Lymphomas Treatment (PDQ®)–Health Professional Version. National Cancer Institute. August 16, 2024.
  30. Cancer Stat Facts: Non-Hodgkin Lymphoma. National Cancer Institute.
  31. Peripheral T-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version. National Cancer Institute. October 4, 2024.
  32. Adult T-cell Lymphoma. Leukaemia Foundation. May 22, 2024.
  33. Understanding Cutaneous Lymphoma. Fred Hutch Cancer Center.
  34. Dippel E et al. S2k‐Guidelines – Cutaneous lymphomas (ICD10 C82 ‐ C86): Update 2021. PubMed. April 21, 2022.
conor-steuer-bio

Conor Steuer, MD

Medical Reviewer

Conor E. Steuer, MD, is medical oncologist specializing in the care of aerodigestive cancers, mesothelioma, and thymic malignancies and an assistant professor in the department of hematology and medical oncology at the Emory University School of Medicine in Atlanta. He joined the clinical staff at Emory's Winship Cancer Institute as a practicing physician in July 2015. He currently serves as chair of the Lung and Aerodigestive Malignancies Working Group and is a member of the Discovery and Developmental Therapeutics Research Program at Winship.

Dr. Steuer received his medical degree from the New York University School of Medicine in 2009. He completed his postdoctoral training as a fellow in the department of hematology and medical oncology at the Emory University School of Medicine, where he was chief fellow in his final year.

He has been active in research including in clinical trial development, database analyses, and investigation of molecular biomarkers. He is interested in investigating the molecular biology and genomics of thoracic and head and neck tumors in order to be able to further the care of these patient populations. Additionally, he has taken an interest in utilizing national databases to perform clinical outcomes research, as well as further investigate rare forms of thoracic cancers.

Steuer's work has been published in many leading journals, such as Cancer, the Journal of Thoracic Oncology, and Lung Cancer, and has been presented at multiple international conferences.

Joseph Bennington-Castro

Author

Joseph Bennington-Castro is a science writer based in Hawaii. He has written well over a thousand articles for the general public on a wide range topics, including health, astronomy, archaeology, renewable energy, biomaterials, conservation, history, animal behavior, artificial intelligence, and many others.

In addition to writing for Everyday Health, Bennington-Castro has also written for publications such as Scientific American, National Geographic online, USA Today, Materials Research Society, Wired UK, Men's Journal, Live Science, Space.com, NBC News Mach, NOAA Fisheries, io9.com, and Discover.